Latest News for: eisai (company)

Edit

Newron presents 2024 financial results and provides 2025 outlook

Pharmiweb 01 Apr 2025
In December 2024, the Company announced a licensing agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories.
Edit

Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, ...

GetNews 28 Mar 2025
Peripheral T-cell Lymphoma companies working in the market are Eisai, Celgene Corporation, HUYA Bioscience International/Quintiles, Verastem, BeiGene, Merck Sharp & Dohme Corp, Solasia Pharma, Aileron Therapeutics, Incyte, Novartis, and others.
Edit

Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, ...

GetNews 26 Mar 2025
Ltd, EMD Serono, Incyte Corporation, Eisai Inc., Parexel, and others ... In December 2024, Nuvation Bio Inc., a global biopharmaceutical company dedicated to addressing unmet oncology needs, announced that the U.S ... Eisai Inc ... Company Name.
Edit

Dravet Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, ...

GetNews 26 Mar 2025
The Key Dravet Syndrome Companies in the market include - Takeda, Eisai, Stoke Therapeurtics, EpyGenix Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Inc, Zogenix International Ltd, Inc., ...
Edit

Angle PLC Announces Results of Eisai Phase 2 pilot study

ACCESSWIRE 21 Mar 2025
UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT ... ANGLE has also successfully completed its contract with the global pharmaceutical company, Eisai Inc ... Results of Eisai Phase 2 pilot study.
Edit

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Pharmiweb 21 Mar 2025
(“Epizyme”), an Ipsen company, outside China ... TAZVERIK® is commercialized by Epizyme in the US and by Eisai in Japan. TAZVERIK® is a registered trademark of Epizyme Inc., an Ipsen company ... company.
Edit

Lewy Body Dementia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports ...

GetNews 19 Mar 2025
CGTX), a clinical-stage company focused on developing treatments for neurodegenerative disorders, announced that Dr ... Key Lewy Body Dementia Companies ... Lewy Body Dementia Therapies and Key Companies ... Eisai ... Eisai Inc ... Eisai Co., Ltd ... Company Name.
  • 1
×